Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 2/20 | 0.50 |
| ▸ | RXRA | P19793 | 1/20 | 0.47 |
| ▸ | RXRG | P48443 | 1/20 | 0.47 |
| ▸ | MRGPRX4 | Q96LA9 | 4/20 | 0.46 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.44 |
| ▸ | GPBAR1 | Q8TDU6 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 2/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | TMPRSS4 | Q9NRS4 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | XDH | P47989 | 1/20 | 0.39 |
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | VNN1 | O95497 | 1/20 | 0.38 |
| ▸ | DDR1 | Q08345 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29488327 | 0.84 | MRGPRX4 (0.57) | CES2RXRARXRGMRGPRX4TAS2R14 | |
| SCHEMBL545065 | 0.84 | MRGPRX4 (0.57) | CES2RXRARXRGMRGPRX4TAS2R14 | |
| SCHEMBL2789789 | 0.83 | CES2 (0.50) | CES2RXRARXRGMRGPRX4TAS2R14 | |
| SCHEMBL2393798 | 0.83 | CES2 (0.50) | CES2RXRARXRGMRGPRX4TAS2R14 | |
| SCHEMBL2562131 | 0.83 | EPHX2 (0.39) | RXRARXRGMRGPRX4KIF11VNN1 | |
| SCHEMBL11875236 | 0.81 | GSK3B (0.40) | MEN1KMT2A | |
| SCHEMBL5222486 | 0.81 | GSK3B (0.40) | MRGPRX4MEN1KMT2A | |
| SCHEMBL322157 | 0.81 | CES2 (0.67) | CES2RXRARXRG | |
| SCHEMBL28798652 | 0.79 | RXRA (0.47) | CES2RXRARXRGMRGPRX4TAS2R14 | |
| SCHEMBL29656570 | 0.79 | RXRA (0.47) | CES2RXRARXRGMRGPRX4TAS2R14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9303000-B2 | Olefin containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-04-05 | — | — | US | disclosed |
| US-9303000-B2 | Olefin containing nuclear transport modulators and uses thereof | Karyopharm Therapeutics Inc. (US) | 2016-04-05 | — | — | US | disclosed |
| EP-2665362-B1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2665362-B1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS INC (US) | 2016-03-30 | — | — | EP | disclosed |
| EP-2665362-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | Karyopharm Therapeutics, Inc. (US) | 2013-11-27 | — | — | EP | disclosed |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-10-11 | — | — | US | disclosed |
| WO-2012099807-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2012099807-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | KARYOPHARM THERAPEUTICS, INC. (US) | 2012-07-26 | — | — | WO | disclosed |
| WO-2009151626-A1 | SUBSTITUTED (1, 2, 4-0XADIAZ0L-3-YL) INDOLIN-1-YL CARBOXYLIC ACID DERIVATIVES USEFUL AS S1P1 AGONISTS | ARENA PHARMACEUTICALS, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258986-A1 | OLEFIN CONTAINING NUCLEAR TRANSPORT MODULATORS AND USES THEREOF | NXF1, NCOA1, XPO1 | CES2 4724/4885RXRA 1911/4885RXRG 1645/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.